Advertisement

 

 

A New Drug to Fight Asthma Exacerbation?

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Mepolizumab, an experimental monoclonal antibody against interleukin, appears to be effective and well tolerated as a treatment for reducing the risk of asthma exacerbations in patients with severe eosinophilis asthma. A clinical trial conducted in 13 countries showed that patients receiving three different doses of mepolizumab had reductions in exacerbation rates that were considered clinically significant.

Abstract: Lancet, August 18, 2012 (online).

Submit a Comment

Your email address will not be published. Required fields are marked *

eleven − two =

[ HIDE/SHOW ]